Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V leiden mutation (resistance to activated protein C)

American Journal of Cardiology

Volumn 84, Issue 5, 1999, Pages 549-554

  Glueck, Charles J ^a   Wang, Ping ^a   Fontaine, Robert N ^a   Tracy, Trent ^a   Sieve Smith, Luann ^a   Lang, James E ^a  

^a JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; CARDIOLIPIN ANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; ESTROGEN THERAPY; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SMOKING; THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; AGED; ARTERIOSCLEROSIS; CROSS-SECTIONAL STUDIES; ESTROGEN REPLACEMENT THERAPY; FACTOR V; FEMALE; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; RISK; THROMBOEMBOLISM;

EID: 0032856643     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00375-6     Document Type: Article

References (29)

1. Glueck C.J., Lang J., Hamer T., Tracy T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med. 123:1994;59-64.
2. Glueck C.J., Scheel D., Fishback J., Steiner P. Estrogen-induced pancreatitis in patients with previously covert familial type V hyperlipoproteinemia. Metabolism. 21:1972;657-666.
3. Davidoff F., Tishler S., Rosoff C. Marked hyperlipemia and pancreatitis associated with oral contraceptive therapy. N Engl J Med. 289:1973;552-555.
4. Stone N.J. Estrogen-induced pancreatitis a caveat worth remembering . J Lab Clin Med. 123:1994;18-19.
5. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
6. Glueck C.J., Lang J.E. Lipoprotein metabolism in the elderly. Abrams W.B., Beers M.H., Berkow R.B. The Merck Manual of Geriatrics. 1995;1023-1052 Merck and Co, Rahway, NJ.
7. Glueck C.J., Freiberg R., Gruppo R., Crawford A., Roy D., Brandt G., McMahon R.E., Bouquot J., Tracy T., Stroop D., Wang P., Becker A. Thrombophilia and hypofibrinolysis reversible pathogenetic etiologies of osteonecrosis in adults and in children (Legg-Perthes disease). AOA International Symposium on Osteonecrosis . Urbaniak J.R., Jones J.P. Jr. Osteonecrosis Etiology, Diagnosis, and Treatment . 1997;105-110 American Academy of Orthopedic Surgeons, Rosemont, IL.
8. Glueck C.J., Shaw P., Lang J., Tracy T., Sieve-Smith L., Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic women. Am J Cardiol. 75:1995;132-136.
9. Glueck C.J., Glueck H.I., Tracy T., Speirs J., McCray C., Stroop D. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism. 42:1993;236-246.
10. Brandt G., Gruppo R., Glueck C.J., Stroop D., Becker A., Pillow A., Wang P. Sensitivity, specificity, and predictive value of modified assays for activated protein C resistance in children. Thromb Haemost. 79:1998;567-570.
11. SAS/STAT User's Guide. Release 6.03 edition. SAS institute Inc. Cary, NC, 1988.
12. Sokal R., Rohlf F. Biometry. 1981;W. H. Freeman and Company, New York.
13. Glueck C.J., McMahon R.E., Bouquot J., Triplett D., Gruppo R., Wang P. Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens. J Lab Clin Med. 130:1997;540-543.
14. Glueck C.J., McMahon R.E., Bouquot J.E., Triplett D. Exogenous estrogen may exacerbate thrombophilia, impair bone healing, and contribute to development of chronic facial pain. Cranio, Craniomandibular Practice. 16:1998;143-153.
15. Henkens C.M., Bom V.J., Seinen A.J., Van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost. 73:1996;402-404.
16. Caine Y.G., Bauer K.A., Barzegar S., ten Cate H., Sacks F.M., Walsh B.W., Schiff I., Rosenberg R.D. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 68:1992;392-395.
17. Price D.T., Ridker P.M. Factor V Leiden mutation and the risks for thromboembolic disease a clinical perspective . Ann Intern Med. 127:1997;895-903.
18. Bauersachs R., Lindhoff-Last E., Erhly A.M., Kuhl H. Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives. Zentralbl Gynakol. 118:1996;262-270.
19. Rosendaal F.R., Siscovick D.S., Schwartz S.M., Beverly R.K., Psaty B.M., Longstreth W.T. Jr, Raghunathan T.E., Koepsell T.D., Reitsma P.H. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 89:1997;2817-2821.
20. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;(suppl M):M8-14.
21. Bontempo F.A., Hasett A.C., Faruki H., Steed D.L., Webster M.W., Makaroun M.S. The Factor V Leiden mutation spectrum of thrombotic events and laboratory evaluation . J Vasc Surg. 25:1997;271-276.
22. Eskandari M.K., Bontempo F.A., Hassett A.C., Faruki H., Makaroun M.S. Arterial thromboembolic events in women with the factor V Leiden mutation. Am J Surg. 176:1998;122-125.
23. Hallak M., Senderowisz J., Cassel A., Shapira C., Aghai E., Auslender R., Abramovili H. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol. 176:1997;889-893.
24. Kiechl S., Muigg A., Santer P., Mitterer M., Egger G., Oberhollenzer M., Oberhollenzer F., Mayr A., Gasperi Arno, Poewe W., Willeit J. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation. 99:1999;614-619.
25. Hultin M.B., Grimson R.C. Factor V Leiden, prothrombin 20210 gene variant, and risk of myocardial infarction. Circulation. 99:1999;457-458.
26. Lalouschek W., Aull W., Serles W., Schnider P., Mannhalter C., Pabinger-Fasching I., Deecke L., Zeiler K. C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke a case-control study . Thromb Res. 93:1999;61-69.
27. Zenz W, Bodo Z, Plotho J, Streif W, Male C, Bernert G, Rauter L, Ebetsberger G, Kaltenbrunner K, Kurnik P, Lischka A, Paky F, Ploier R, Hofler G, Mannhalter C, Muntean W. Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke. Thromb Haemost 1998;80:763-736.
28. Ridker P.M., Hennekens C.H., Lindpainter K., Stampfer M.J., Eisenberg P.R., Miletich J.P. Mutation in the gene coding for coagulation Factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 332:1995;912-917.
29. Cushman M., Rosendaal F.R., Psaty B.M., Cook E.F., Valliere J., Kuller L.H., Tracy R.P. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly results from the Cardiovascular Health Study . Thromb Haemost. 79:1998;912-915.